CD274 and neoplasm: Within this context, the PD-L1 expression on tumor surface is currently used as one of the biomarkers to assess eligibility for immunotherapy, along with microsatellite instability (MSI) and tumor mutational burden (TMB)—of note, all these markers are rarely concordant, but each of them suffices as a marker [40].